Cantor Fitzgerald Weighs in on VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Voyager Therapeutics in a research note issued to investors on Monday, January 13th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will post earnings per share of ($0.98) for the year. Cantor Fitzgerald has a “Overweight” rating and a $5.73 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.89) per share.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the company posted ($0.59) EPS.

Other research analysts have also recently issued reports about the company. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Leerink Partners began coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $15.97.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $5.05 on Tuesday. Voyager Therapeutics has a 1 year low of $5.03 and a 1 year high of $10.66. The stock has a market cap of $275.86 million, a PE ratio of 7.11 and a beta of 0.93. The firm has a fifty day moving average price of $6.07 and a 200-day moving average price of $6.79.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of VYGR. China Universal Asset Management Co. Ltd. lifted its holdings in Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth approximately $74,000. Victory Capital Management Inc. lifted its position in Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after buying an additional 1,630 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Voyager Therapeutics in the 2nd quarter worth $128,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Voyager Therapeutics in the third quarter valued at about $216,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.